2016-11-14T09:05:45-06:00 2015-12-31 521853933 JONES MARESCA & MCQUADE PA 10500 LITTLE PATUXENT PARKWAY SUITE 770 COLUMBIA MD 21044 990 2015-01-01 522320756 ACCELERATE BRAIN CANCER CURE INC ACCE 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 MAX WALLACE PRESIDENT AND CEO 2024193140 2016-11-10 1 DAVID JONES P01361002 4108840220 2015 2017-02-10 21:41:12Z MAX WALLACE 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 2896244 0 X WWW.ABC2.ORG X 2001 DC ACCELERATE BRAIN CANCER CURE HAS A SINGLE FOCUS-TO HASTEN THE DISCOVERY OF A CURE FOR BRAIN CANCER. 9 8 8 9 0 0 1933475 2377196 0 0 649 -9813 0 0 1934124 2367383 290000 1401606 0 0 829080 706124 0 0 638374 389621 495461 1508701 2603191 425423 -235808 3457295 3538389 117979 434881 3339316 3103508 THE PRIMARY OBJECTIVE OF ACCELERATE BRAIN CANCER CURE, INC. IS TO ACCELERATE PROGRESS IN WHAT HAS BEEN AN UNDERSERVED FIELD OF RESEARCH; THE ORGANIZATION AIMS TO RAISE AWARENESS ABOUT BRAIN CANCER AND HELP MOBILIZE CRITICAL SCIENTIFIC RESEARCH THROUGH RESEARCH GRANTS. 0 0 1659417 1401606 ACCELERATE BRAIN CANCER CURE, INC. (ABC2) BELIEVES A FOCUSED AND AGGRESSIVE ENTREPRENEURIAL MODEL WILL INCREASE THE NUMBER OF THERAPIES DISCOVERED AND ENABLE THOSE THERAPIES TO BE AVAILABLE TO DOCTORS AND PATIENTS MORE QUICKLY. ABC2 PROVIDES RESEARCHERS WITH THE PIVOTAL SUPPORT THEY NEED TO MAKE CRITICAL BREAKTHROUGHS. IT FUNDS TRANSLATIONAL RESEARCH AIMED AT FINDING THE FASTEST POSSIBLE ROUTE TO A CURE. ABC2 SUPPORTS A RANGE OF MEDICAL RESEARCH ORGANIZATIONS. 1659417 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 0 0 0 1 1 0 0 1 0 0 1 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 1 26 0 1 8 1 0 0 0 0 0 0 0 0 0 0 X 9 8 1 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 0 0 CA X THE ORGANIZATION 2024193140 1717 RHODE ISLAND AVENUE NW NO 700 WASHINGTON DC 20036 STACEY CASE CO-FOUNDER 1.00 X 0 0 0 STEPHEN CASE CHAIRMAN & CO-FOUNDER 1.00 X 0 0 0 NANCY PFUND MEMBER 1.00 X 0 0 0 DAVID COLE MEMBER 1.00 X 0 0 0 JEAN CASE CO-FOUNDER 1.00 X 0 0 0 DOUG HOLLADAY MEMBER 1.00 X 0 0 0 LARRY PROBST MEMBER 1.00 X 0 0 0 JONATHAN WEINBERG MEMBER 1.00 X 0 0 0 GARY WIMMER MEMBER 1.00 X 0 0 0 MAX WALLACE CHIEF EXECUTIVE OFFICER 40.00 X 250855 0 12856 DAVID SANDAK VP, SECRETARY/TREASURER 40.00 X 141713 0 30604 392568 0 43460 2 0 1 0 0 1496172 881024 287571 2377196 2017 2017 275740 287570 -11830 -11830 -11830 241291 1496172 241291 0 2367383 0 0 -9813 1401606 1401606 436028 41514 106983 287531 183448 22793 63711 96944 12009 1770 2026 8213 33108 11043 6975 15090 41531 6698 9489 25344 854 854 48800 48800 210595 96641 35446 78508 19762 5617 3293 10852 114586 10632 103954 14870 3600 7670 3600 44398 44040 299 59 3739 3739 20827 14800 6027 MEALS AND ENTERTAINMENT 8845 8441 310 94 LICENSE AND REGISTRATIO 8185 8185 2603191 1659417 305400 638374 2634925 2696483 592003 695347 26447 27087 32154 22949 7582 9205 196315 110252 23 15 3457295 3538389 98715 54046 380835 11690 7574 0 117979 434881 X 2747313 2365040 592003 738468 3339316 3103508 3457295 3538389 -235808 0 X X 0 1 X 1 0 X 2057633 1874906 3168066 2154714 2575366 11830685 2057633 1874906 3168066 2154714 2575366 11830685 1201063 10629622 693 208 215 649 2017 3782 22134 22134 11856601 0.89650 0.90230 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 32154 22949 9205 9205 X 2704543 95869 241291 337160 2367383 0 2367383 2940351 95869 241291 337160 2603191 0 2603191 PART X, LINE 2: ABC2 BELIEVES THAT IT HAS APPROPRIATE SUPPORT FOR ANY TAX POSITIONS TAKEN, AND AS SUCH, DOES NOT HAVE ANY UNCERTAIN TAX POSITIONS THAT ARE MATERIAL TO THE FINANCIAL STATEMENTS OR THAT WOULD HAVE AN EFFECT ON ITS TAX-EXEMPT STATUS. THERE ARE NO UNRECOGNIZED TAX BENEFITS OR LIABILITIES THAT NEED TO BE RECORDED. PART XI, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 241,291. PART XII, LINE 2D - OTHER ADJUSTMENTS: DIRECT FUNDRAISING EXPENSES 241,291. 1 MIDDLE EAST AND NORTH AFRICA 0 0 GRANTS TO RECIPIENTS LOCATED IN THIS REGION GRANTS GIVEN FOR TREATMENT OF GLIOBLASTOMA USING THE "SPLIT IMMUNITY" MODE OF VACCINATION. 500000 0 0 0 0 0 0 500000 0 500000 MIDDLE EAST AND NORTH AFRICA FOR TREATMENT OF GLIOBLASTOMA USING THE "SPLIT IMMUNITY" MODE OF VACCINATION; 500000 1 0 0 0 0 0 0 PART I, LINE 2: ABC2 CLOSELY MONITORS THE PROGRESS OF THE RESEARCHERS IT FUNDS THROUGH ITS GRANT PROGRAM. THE ORGANIZATION REQUIRES SCIENTIFIC PROGRESS REPORTS AND COMPLETE FINANCIAL ACCOUNTING OF EXPENDITURES BEFORE RELEASING ADDITIONAL FUNDS AS WELL AS FINAL GRANT REPORTS INCLUDING FINANCIAL REPORTS. IN ADDITION, ABC2 HOLDS AN ANNUAL SCIENTIFIC MEETING AT WHICH TIME CERTAIN GRANTEES PRESENT THEIR PROGRESS. RACE FOR HOPE FUNDRAISING EVENT-DC 1161939 1042035 119904 119904 FLORIDA RACE 242734 202616 40118 40118 4 332790 251521 81269 81269 1737463 1496172 241291 241291 241291 0 1 FLORIDA CENTER FOR BRAIN TUMOR RESEARCH - UNIVERSITY OF FLORIDA HEALTH 591943502 100000 BRAIN TUMOR RESEARCH GRANT PROGRAM. NATIONAL BRAIN TUMOR SOCIETY INC 55 CHAPEL STREET SUITE 200 NEWTON MA 02458 043068130 C(3) 7500 TO SUPPORT THE COST OF PUBLISHING A NEURO-ONCOLOGY JOURNAL SUPPLEMENT WITH BACKGROUND PAPERS FROM THE OCTOBER 14, 2014 WORKSHOP OF CLINICAL OUTCOMES ASSESSMENTS. SYAPSE INC 101 UNIVERSITY AVENUE SUITE 230 PALO ALTO CA 94301 263457459 183160 TO GATHER BIOBANK INFORMATION FROM A WIDELY DIVERSE PATIENT POPULATION BY GIVING 1,000 BRAIN CANCER PATIENTS FREE GENETIC SEQUENCING OF THEIR BRAIN TUMORS. THE TRUSTEES OF COLUMBIA UNIVERSITY 131943502 C(3) 180111 GLIOBLASTOMA LIVING BIOBANK, SCREEN COMPOUNDS IN PATIENT-DERIVED GLIOBLASTOMA (GBM) LINES TO IDENTIFY MECHANISMS ENABLING POTENT AND SELECTIVE KILLING OF GBM. UNIVERSITY OF NORTH CAROLINA 103 SOUTH BUILDING CHAPEL HILL NC 27599 566001393 C(3) 150000 THERAPEUTIC DISCOVERY PLATFORM TARGETING GLIOMA-INITIATING CELLS. STEMCYCLE INC (NOTABLE LABS) 471375681 50000 TO DEVELOP A PLATFORM TO CULTIVATE PATIENT DERIVED NEUROSPHERE AND XENOGRAFT GLIOMA MODELS TO SCREEN COMPOUNDS IN ORDER TO IDENTIFY COMBINATION BRAIN CANCER THERAPIES; EIN:TO DEVELOP A PLATFORM TO CULTIVATE PATIENT DERIVED NEUROSPHERE AND XENOGRAFT GLIOMA MODELS TO SCREEN COMPOUNDS IN ORDER TO IDENTIFY COMBINATION BRAIN CANCER THERAPIES; EIN:TO DEVELOP A PLATFORM TO CULTIVATE PATIENT DERIVED NEUROSPHERE AND XENOGRAFT GLIOMA MODELS TO SCREEN COMPOUNDS IN ORDER TO IDENTIFY COMBINATION BRAIN CANCER THERAPIES; EIN:TO DEVELOP A PLATFORM TO CULTIVATE PATIENT DERIVED NEUROSPHERE AND XENOGRAFT GLIOMA MODELS TO SCREEN COMPOUNDS IN ORDER TO IDENTIFY COMBINATION BRAIN CANCER THERAPIES. UNIVERSITY OF CALIFORNIA SAN DIEGO 5995 ALCALA PARK SAN DIEGO CA 92110 952544535 C(3) 230835 IMMUNOSIGNATURE STRATEGY FOR DEVELOPMENT OF CLINICAL BIOMARKERS AND IDENTIFICATION OF NEW DRUG TARGET CANDIDATES FOR PEDIATRIC BRAIN CANCER. FOR TREATMENT OF GLIOBLASTOMA USING THE "SPLIT IMMUNITY" MODE OF VACCINATION; EIN: FOREIGN ENTITYFOR TREATMENT OF GLIOBLASTOMA USING THE "SPLIT IMMUNITY" MODE OF VACCINATION; EIN: FOREIGN ENTITYFOR TREATMENT OF GLIOBLASTOMA USING THE "SPLIT IMMUNITY" MODE OF VACCINATION. 4 3 PART I, LINE 2: ABC2 CLOSELY MONITORS THE PROGRESS OF THE RESEARCHERS IT FUNDS THROUGH ITS GRANT PROGRAM. THE ORGANIZATION REQUIRES SCIENTIFIC PROGRESS REPORTS AND COMPLETE FINANCIAL ACCOUNTING OF EXPENDITURES BEFORE RELEASING ADDITIONAL FUNDS AS WELL AS FINAL GRANT REPORTS INCLUDING FINANCIAL REPORTS. IN ADDITION, ABC2 HOLDS AN ANNUAL SCIENTIFIC MEETING AT WHICH TIME CERTAIN GRANTEES PRESENT THEIR PROGRESS. X X X 0 0 0 0 0 0 0 0 0 MAX WALLACE CHIEF EXECUTIVE OFFICER 250855 0 0 0 0 0 0 0 12856 0 263711 0 0 0 DAVID SANDAK VP, SECRETARY/TREASURER 141713 0 0 0 0 0 5901 0 24703 0 172317 0 0 0 X 1 287571 FAIR MARKET VALUE 0 0 0 FORM 990, PART VI, SECTION A, LINE 2 STEPHEN CASE, CHAIRMAN & BOARD MEMBER AND JEAN CASE, BOARD MEMBER ARE CO-FOUNDERS AND SPOUSES. STACEY CASE, BOARD MEMBER AND CO-FOUNDER, IS THE SISTER-IN-LAW OF STEPHEN CASE. THESE BOARD MEMBERS ALSO HAVE BUSINESS RELATIONSHIPS. FORM 990, PART VI, SECTION B, LINE 11 MAX WALLACE, THE CHIEF EXECUTIVE OFFICER OF ACCELERATE BRAIN CANCER CURE, INC. REVIEWS AND SIGNS THE 990. THE 990 IS ALSO REVIEWED BY THE FINANCE COMMITTEE BEFORE IT IS FILED. FORM 990, PART VI, SECTION B, LINE 12C THE BOARD OF DIRECTORS REVIEWS THE CONFLICT OF INTEREST POLICY AT ITS ANNUAL BOARD MEETING. INDEPENDENCE IS ALSO CONFIRMED PRIOR TO THE AWARDING OF ANY EXPENDITURE RESPONSIBILITY GRANT. FORM 990, PART VI, SECTION B, LINE 15A THE CHIEF EXECUTIVE OFFICER JOINED THE ORGANIZATION IN 2008. AS PART OF THE EXECUTIVE SEARCH PROCESS AN INDEPENDENT SEARCH FIRM PERFORMED AN INDUSTRY COMPENSATION ANALYSIS. THE LAST COMPENSATION REVIEW TOOK PLACE ON DECEMBER 2015. THE ORGANIZATION HAD NO KEY EMPLOYEES. FORM 990, PART VI, SECTION C, LINE 19 THE ORGANIZATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANICAL STATEMENTS AVAILABLE FOR PUBLIC INSPECTION UPON REQUEST. FORM 990, PART XII, LINE 2C THIS PROCESS HAS NOT CHANGED FROM THE PRIOR YEAR.